Anti-IgG4 antibody (Full length) [ZR299] (STJ180420)
SPECIFICATIONS
ClonalityMonoclonal
HostRabbit
ConjugationUnconjugated
IsotypeIgG
ImmunogenRecombinant full-length human IGHG4 protein
General Information
| Short Description | Rabbit monoclonal IgG4 (Full length) antibody for use in IHC-P in human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | IHC-P |
| Host | Rabbit |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Clone ID | ZR299 |
| Isotype | IgG |
| Conjugation | Unconjugated |
| Purification | Affinity purified |
| Dilution Range | 1:100-200 |
| Formulation | Tris-HCI buffer containing stabilizing protein (BSA) and <0.1% ProClin |
| Storage Instruction | Store at 2β8Β°C for up to 24 months. Predilute: Ready to use, no reconstitution necessary. Concentrate: Use dilution range and appropriate labβstandardized diluent. Stability after dilution: 7 days at 24Β°C, 3 months at 2β8Β°C, 6months at β20Β°C. |
Target Information
| Gene Symbol | IGHG4Uniprot ID=IGHG4_HUMAN" |
| Immunogen | Recombinant full-length human IGHG4 protein |
| Immunogen Region | Full length |
| Specificity | Positive control: Tonsil |
Additional Info
| Post Translational Modifications | Glycosylation on Asn-177 is required for interaction with Fc receptors and ability to activate the complement pathway. (Microbial infection) Deglycosylation on Asn-177 by S.pyogenes EndoS or Endos2 endoglucosidases prevents interaction between immunoglobulin-gamma (IgG) and Fc receptors, impairing ability to activate the complement pathway. |
| Function | Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens. The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen. |
| Protein Name | Immunoglobulin Heavy Constant Gamma 4Ig Gamma-4 Chain C Region |
| Cellular Localisation | Isoform 1: SecretedIsoform 2: Cell MembraneSingle-Pass Membrane Protein |
| Alternative Antibody Names | Anti-Immunoglobulin Heavy Constant Gamma 4 antibodyAnti-Ig Gamma-4 Chain C Region antibodyAnti-IGHG4 antibody |
Information sourced from Uniprot.org